News

January 23, 2020January 23, 2020

Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo

News

Exelixis will expand its Phase 1b clinical trial evaluating a combination of Cabometyx (cabozantinib) with Tecentriq (atezolizumab) to include more patients with metastatic castration-resistant prostate cancer (mCRPC), based on ... Read more

January 22, 2020January 22, 2020

FDA Grants Priority Review to Lynparza as Treatment for Mutated Metastatic Castration-resistant Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has granted priority review status to an application to extend the use of the oral therapy Lynparza (olaparib) to men with metastatic castration-resistant ... Read more

January 20, 2020

Zuclomiphene Safely Eases Hot Flashes Linked to ADT Use, Phase 2 Trial Reports

News

Interim Phase 2 trial results show that Veru‘s experimental treatment zuclomiphene citrate is well-tolerated and significantly reduces hot flashes in advanced prostate cancer patients using androgen deprivation therapy (ADT). ... Read more

January 16, 2020January 16, 2020

Rubraca Granted FDA Priority Review for Advanced Prostate Cancer with BRCA Mutations

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) for treating men with recurrent metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations. The priority review ... Read more

January 15, 2020January 15, 2020

Advaxis Seeks FDA Approval to Begin Phase 1 Trial of its ADXS-504 Immunotherapy for Prostate Cancer

News

Advaxis is seeking permission from the U.S. Food and Drug Administration (FDA) to start the first Phase 1 clinical trial of ADXS-504, a potential immunotherapy for prostate cancer. Cancer ... Read more

January 13, 2020January 13, 2020

Veyonda Plus Low-dose Radiotherapy May Halt Disease Progression in Late-Stage PC, Study Suggests

News

Noxopharm’s Veyonda (idronoxil), in combination with low-dose radiation therapy, safely halted disease progression and eased pain in men with late-stage metastatic castration-resistant prostate cancer (mCRPC), according to results from a Phase 1b ... Read more

January 8, 2020

US Congress Increases Funding for Prostate Cancer Research for FY 2020

News

To foster more research projects in prostate cancer, the U.S. Congress has increased funding for the Department of Defense’s Prostate Cancer Research Program (PCRP) by $10 million, to $110 million, ... Read more

January 6, 2020

EMA Committee Favors Extending Use of Erleada for Metastatic Castration-sensitive Prostate Cancer

News

The Committee for Medicinal Products for Human Use recommends extending the use of Janssen’s Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), to treat men with metastatic hormone-sensitive prostate ... Read more

December 30, 2019January 9, 2020

PyL Imaging Agent Accurately Detects Recurrent Prostate Cancer Lesions, Trial Shows

News

Progenics Pharmaceuticals’ PyL, a new imaging agent for positron emission tomography (PET) scans, can accurately detect the location of recurrent prostate cancer lesions, according to data from a Phase 3 clinical trial. ... Read more

December 19, 2019December 19, 2019

Lynparza Particularly Effective in Prostate Cancer Patients Carrying BRCA Mutations, Phase 2 Study Shows

News

Lynparza (olaparib), a breast and ovarian cancer treatment, is also showing promising results in men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in DNA repair genes, particularly ... Read more

Pin It on Pinterest